Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders
held its 2017 Annual Meeting of Stockholders (the “Annual
Meeting”). As of April 17, 2017, the record date for the Annual
Meeting, 33,078,518 shares of common stock were outstanding and
entitled to vote at the Annual Meeting. A summary of the matters
voted upon by stockholders at the Annual Meeting is set forth
below.
present at the meeting in person or by proxy, which represents
approximately 81.58% of the shares of common stock outstanding as
of the record date for the Annual Meeting.
as Class III Directors, each to serve until the Companys 2020
Annual Meeting of Stockholders and until their successors are
duly elected and qualified. The final voting results are as
follows:
|
Name of Director Nominee:
|
|
Votes For
|
|
Votes Withheld
|
|
Broker Non-Votes
|
|||
|
Richard A. Fair
|
|
20,306,286
|
|
109,381
|
|
6,570,092
|
|||
|
James M. Daly
|
|
19,577,073
|
|
838,594
|
|
6,570,092
|
|||
|
Reid M. Huber, Ph.D.
|
|
19,289,139
|
|
1,126,528
|
|
6,570,092
|
Company’s 2014 Equity Incentive Plan, as amended (the “Plan”),
to, among other things, increase the number of shares of common
stock authorized for issuance under the Plan by 3,100,000 shares
and eliminate the current provision in the Plan that permits the
Board to reprice stock options without stockholder approval. The
final voting results are as follows:
|
|
|
Votes For
|
|
Votes Against
|
|
Abstention
|
|
Broker Non-Votes
|
||||
|
|
|
11,065,292
|
|
4,187,833
|
|
5,162,542
|
|
6,570,092
|
Registered Public Accounting Firm
LLP by the Audit Committee of the Company’s Board of Directors
to serve as the Companys independent registered public accounting
firm for the fiscal year ending December 31, 2017. The final
voting results are as follows:
|
|
|
Votes For
|
|
Votes Against
|
|
Abstention
|
|
|
|||
|
|
|
25,577,768
|
|
1,153,849
|
|
254,142
|
|
|
About Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)
Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company’s product candidates include BPX-501, BPX-401, BPX-601 and BPX-701. BPX-501 is an adjunct T cell therapy for allogeneic hematopoietic stem cell transplantation. The Company’s CID-based technologies include CaspaCIDe, CIDeCAR and GoCAR-T.
